Latest Commercialization News

3D Energi Limited has updated its prospective gas resource estimates in the Otway Basin, revealing a substantial 9.2 trillion cubic feet (Tcf) of gross recoverable gas across 51 prospects. The company is gearing up for a multi-well drilling campaign in 2025 targeting near-term commercialisation opportunities to bolster East Coast energy security.

TMK Energy is set to drill a new pilot well at its Gurvantes XXXV Coal Seam Gas Project and is making headway in securing strategic partnerships, particularly with Chinese companies experienced in horizontal drilling and fracking.

SciDev Limited has secured $21.5 million in new contracts and renewals across oil & gas, mining, and PFAS remediation sectors, boosting its FY26 revenue guidance to $120-$140 million.

Anson Resources has partnered with POSCO Holdings to develop a demonstration plant for Direct Lithium Extraction at the Green River Lithium Project, aiming to validate new technology and boost US lithium supply.

QPM Energy Limited has launched the Isaac Energy Hub with its first stage, a 112MW gas-fired power station, aiming for mid-2027 commissioning. The company is raising $12 million to support project development and expand its integrated energy utility footprint.

Cambium Bio has secured ethics approvals in Australia and the US to initiate pivotal Phase 3 trials of Elate Ocular, targeting moderate to severe dry eye disease, with patient dosing expected in October 2025.

Actinogen Medical has locked in up to $13.8 million in non-dilutive funding tied to its R&D tax incentives, bolstering its cash position as it advances a pivotal Alzheimer’s disease clinical trial.

Theta Gold Mines has approved the Decision to Mine for its TGME Gold Project in South Africa and raised US$4 million through a private placement, advancing its path toward production amid rising gold prices.

NH3 Clean Energy has successfully raised $710,000 through a share placement, boosting funding for its WAH2 clean ammonia export project. This capital injection, alongside convertible note conversions, underscores progress toward the project's final investment decision.

Dimerix Limited has received a significant milestone payment from its Japanese partner FUSO Pharmaceutical, marking progress in the Phase 3 clinical trial of DMX-200 for kidney disease. This payment underscores the growing momentum behind Dimerix’s global licensing strategy.

LTR Pharma has successfully completed the extractables study for its intranasal erectile dysfunction spray SPONTAN, confirming safety compliance and initiating the next phase of leachables testing to support FDA approval.

Brightstar Resources has completed a Definitive Feasibility Study for its Menzies and Laverton Gold Projects, outlining a robust staged development plan with strong financial returns and a targeted final investment decision in 2025.